Bret Jensen

|RSS

Currently the editor of "The Biotech Forum," Bret Jensen was chief investment strategist for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami, from 2008-2011. The fund was in the top 5% of long/short hedge funds for total return in its first full year (2009), as ranked by Hedgeco fund database (more than 450 funds in category). Prior to this, he spent a decade as technology director of a Fortune 100 firm.Expand

Jensen has been a top-5%-ranked financial analyst and blogger since 2013, according to TipRanks. He holds a Bachelor of Science degree in finance from Arizona State University.

Follow Bret on Twitter: @Bret_Jensen.Collapse

By

Bret Jensen

 | Jul 22, 2016 | 12:31 PM EDT
Market staging nice rally to end the week.  Oil down and seems ~$45 a barrel has become the new resistance level from $50 prior to Brexit....
By

Bret Jensen

 | Jul 22, 2016 | 11:00 AM EDT
I expect Allergan or another player to bid for SGYP soon.
By

Bret Jensen

 | Jul 21, 2016 | 11:00 AM EDT
Watch these names as stability returns to the sector.
By

Bret Jensen

 | Jul 21, 2016 | 9:58 AM EDT
Definitely a windshield, not a bug sort of day so far.  Best idea Relypsa (RLYP) is up nearly 60% on all cash takeover offer by Galencia.  ...
By

Bret Jensen

 | Jul 20, 2016 | 12:19 PM EDT
Market is having a nice rally.  Biotech is particularly strong and has erased all of yesterday's declines and then some.  Late yesterday...
By

Bret Jensen

 | Jul 19, 2016 | 2:40 PM EDT
Market mixed as we enter last 90 minutes of trading.  Bifurcated market today.  Biotech getting hit hard with many small biotech concerns...
By

Bret Jensen

 | Jul 19, 2016 | 11:00 AM EDT
Use caution out there, this market feels overbought.
By

Bret Jensen

 | Jul 18, 2016 | 11:40 AM EDT
Market starting off the week on a high note with decent gains across the board.  Seems equities have become immune to overseas events recently...
By

Bret Jensen

 | Jul 18, 2016 | 11:00 AM EDT
The biotech juggernaut still has a lot going for it, especially at these levels.
By

Bret Jensen

 | Jul 15, 2016 | 12:14 PM EDT
Nice to see biotech recover from yesterday's almost two percent swoon even as the overall market is slightly as we go into the homestretch of the...

BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.